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Open access under CC BY license.The occurrence of schistosomiasis within African
infants and preschool children has been much better
documented in recent years, revealing an important
burden of disease previously overlooked. Despite
mounting evidence showing that treatment with prazi-
quantel is safe, beneficial, and could be delivered within
ongoing public health interventions, young children still
do not have satisfactory access to this drug, and a
significant treatment gap exists. Progress towards res-
olution of this unfortunate health inequity is highlight-
ed, including the development of an appropriate
paediatric praziquantel formulation, and present blocks
are identified on securing this issue within the interna-
tional health agenda.
Mind the gap: the need for praziquantel
Five years ago, the treatment needs of African infants and
preschool children afflicted by schistosomiasis (see Glossa-
ry) with the anthelminthic praziquantel (PZQ) were raised
indicating that national control programmes (NCPs)
should consider more formally the health status of these
younger children [1–3]. It was then an open question as to
whether these younger children could or should be includ-
ed within preventive chemotherapy (PC) campaigns. Since
then there have been significant developments to better
document this disease burden by the retargeting of epide-
miological surveys and to better tailor international poli-
cies and practices towards this paediatric setting [4–10].
As several studies come to fruition and as new evidence
emerges, a fresh international dialogue has been estab-
lished with key support and coordination offered by the
World Health Organisation (WHO). This is to ensure the
development of a longer-term framework to manage this
disease at the individual and (or) community level. In so
doing, these studies have heightened the realisation that1471-4922
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unique challenges [7–10]. These include needs for better
diagnostics, revised licensing of PZQ, scaled-up deploy-
ment of available and future PZQ formulation(s), and
sustaining associated drug delivery systems for integrated
control of neglected tropical diseases (NTDs) [5,9].
A key driver behind this new impetus is that overt and
cryptic morbidity commonly attributable to schistosomia-
sis can occur during school age (Figure 1). Any delay in
prompt access to treatment of these younger children
points towards an unfavourable downstream clinical out-
come. Even more importantly is that at the individual
level, these infections cause detrimental onslaughts to
the health of the child during key developmental stages.
Moreover, as NCPs strive towards elimination of infections
by PC alone, or in combination with other measures at the
community level, promotion of access to PZQ treatment for
any infected case, irrespective of their age, becomes ever
more important [11–13]. Conceptually, this is to ensure
that general reductions in parasite transmission are con-
solidated across all community groups [14,15]. Thus, the
need for equitable treatment of younger children has be-
come so obvious that a ‘PZQ treatment gap’ terminology
has been coined [16]. Although mentioned in the WHO
2012–2020 strategic plan, there are still significant blocks
to overcome to embed this issue firmly within the agenda of
NTD control and to see National Control Programmes
embrace this element [17].
First blocks off on PZQ treatment: application and
dosing
Although PZQ is perhaps one of the safest drugs being used
in PC campaigns, there was little formal legislation and
documentation confirming its use in younger children [18–
20]. An age-related cut-off in children aged below 4 years
existed simply due, perhaps, to an incomplete registration
and limited future vision of treatment needs by Bayer and
Merck (see below). Thus, PZQ is administered in ‘off-label’
settings, which make international agencies rather uncom-
fortable without substantial evidence to the contrary, andTrends in Parasitology, April 2013, Vol. 29, No. 4 197
Glossary
London Declaration on Neglected Tropical Diseases (LDNTDs): a high level
advocacy meeting that took place in London in January 2012 that brought
together international donors, the pharmaceutical sector, and implementation
agencies to pledge support for development, donation, and distribution of
drugs to combat NTDs. Further information can be found at http://unitingto-
combatntds.org/downloads/press/ntd_event_london_declaration_on_ntds.pdf.
A year later, the London Centre for Neglected Tropical Diseases was launched
bringing together a new local partnership with Imperial College London (ICL),
London School of Hygiene and Tropical Medicine (LSHTM), and The Natural
History Museum (NHM) working within the UK Coalition against Neglected
Tropical Diseases (http://ntd-coalition.blogspot.co.uk/).
Medical ethics: there are four central tenets to medical ethics. Beneficence (i.e.,
to do good), this will allow infected children, if treated, to achieve a better state
of health given the alternative to absence of medication. Non-maleficence (i.e.,
do no harm), as PZQ has an excellent safety record, even in the absence of
formalised randomised clinical trials, detrimental risks associated with
treatment are negligible. Autonomy (i.e., self-determination), informing the
mothers of infected children about the risks and benefits through informed
consent addresses this principle. Justice (i.e., moral rightness), advocating the
need for social responsibility to provide universal treatment care and treatment
to those that need it.
Morbidity associated with schistosomiasis: disease is typically due to direct
lesions by schistosome eggs and concurrent immunopathology to tissue
granulomata. Manifestations for urogenital schistosomiasis include (macro)-
haematuria and (micro)haematuria where there is visual blood in the urine or
cryptic amounts as detected by reagent strips, respectively. Urine reagent
strips also detect proteinuria, the main biological component being albumin,
which can be graded into various levels of albuminuria. For intestinal
schistosomiasis, although blood can be seen directly in the stool in frank
cases, faecal occult blood (FOB) tests can be used to detect its presence with
greater sensitivity.
National control programmes (NCPs): disease intervention programmes
operating at a national level where a formal commitment in terms of policy,
finances, staffing, and timetabling of a country to adopt and scale-up PC to a
country-wide application. Measurement and assessment of progress towards
reductions in selected disease targets are an obligatory requirement of the
monitoring and evaluation component.
Neglected tropical diseases (NTDs): a group of several tropical diseases that
collectively cause significant mortality and morbidity, often in impoverished
rural communities. Schistosomiasis, alongside other helminthiases, is a key
NTD and can be controlled by PC.
Praziquantel (PZQ): an oral anthelminthic originally discovered by Merck
(Germany) during the 1970s whilst screening for tranquilisers with later
codevelopment with Bayer (Germany). Initially intended for veterinary use, this
safe broad-spectrum dewormer became the treatment of choice for schisto-
somiasis, particularly after off-patent generic drug production reduced
purchasing costs to less than US$0.05 per 600 mg tablet. The drug is formally
licensed and labelled for medical use for adults and children (aged 4 and above
in years), at 40 or 60 mg/kg dosing for schistosomiasis, although lower dosing
is advised for other trematodiasis. There is, however, no formal evidence
capturing pharmacokinetics and pharmacodynamics in children.
Preventive chemotherapy (PC): a community-based treatment strategy, as
endorsed by the WHO, where single administration of deworming medications
such as, ivermectin, albendazole, and praziquantel, are regularly (co)adminis-
tered within communities at significant risk of NTDs often by non-medical
personnel. The intention is that by providing treatment future morbidity is
prevented and disease transmission significantly reduced. For schistosomiasis
children of school age are typically the major focus of treatment targeting.
Schistosomiasis: a water-borne parasitic disease that can be caused by six
species of schistosome. In Africa, two forms of the disease, urogenital and
intestinal, are dominant being caused by Schistosoma haematobium and
Schistosoma mansoni, respectively. As part of its intricate life cycle, the
schistosome needs to develop in freshwater snails. The cercaria, a short-lived
larval stage emerging from the snail, is able to penetrate human skin directly.
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Figure 1. Advanced intestinal schistosomiasis in an 8-year-old child. This young
child was encountered during general disease surveillance activities on the Sesse
Islands, Lake Victoria in November 2010. Clinical presentations such as this are still
common throughout endemic areas of Uganda [60] and warrant better formal
recording if the burden of morbidity in young children is to be quantified. Sadly,
although this child may have received his first praziquantel (PZQ) treatment within
primary school, his individual morbidity is already at an advanced stage and may
not be fully reversible. Had this child had treatment at a preschool age this might
have been averted, which is perhaps a strong indictment that further inaction is
unethical.
Review Trends in Parasitology April 2013, Vol. 29, No. 4with legal indemnity falling upon those who have chosen to
use it under their own discretion. Although this ‘off-label’
phenomenon is often common practice in paediatric ward
settings [21], it did little to assuage the initial ethical, legal,
and insurance-driven arguments against its extended use;
a parallel predicament was the use of PZQ in pregnancy,
which is now endorsed by the WHO in their revised guide-
lines [17].
These counter points of view were much diminished,
after a tipping point was reached when the burden of198disease in young children was firmly demonstrated as
being so alarming that any further inaction should be
considered unethical. There are four key medical tenets
appropriate here: beneficence, non-maleficence, autonomy,
and justice [22], all of which have some bearing upon how
we react to this PZQ treatment gap. Nonetheless how much
more convincing evidence was needed? With the help of the
WHO, a cross-country study was undertaken in Mali,
Niger, Sudan, Uganda, Zimbabwe, and Egypt in 2009
[4,7,23,24]. Here it was the intention to take more formal
steps to develop a portfolio of evidence reporting on its use
in terms of drug safety and performance, although using
crushed or broken tablets versus a liquid suspension. This
was not a formal clinical trial, which has a totally different
set of legal, financial, and registration requirements, but
rather an on-the-ground exploration with the aim of
remedying a glaring health inequality. This was a partic-
ularly seminal and brave first step by the WHO and was
warmly welcomed by the in-country coordinators seeding
the need for further applied research.
Many of the areas where schistosomiasis in preschool
children abounds are often characterised by impoverished
or under-resourced local static health systems [25,26]. For
example, despite trained staff, in rural health clinics there
is often no provision of accurate weighing scales or the
availability of fully functioning diagnostic facilities (i.e.,
urine and faecal examination kits and access to compound
microscopy). Resolution of this weight-based bottleneck
was achieved in general PC campaigns through the use
of a height pole or treatment stick. Until 2012, the existing
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94 cm in stature. Following the work of Sousa-Figueiredo
et al. [9], this has now been comprehensively resolved with
an extensive validation of a downwardly extended height
pole offering dosing at 40 mg/kg at 0.5 (½), 0.75 (3/4) and
single tablet divisions (Box 1). This of course needs tablets
which are scored with quarter divisions, that is, breakable
sections each of 150 mg, which are not always fabricated in
this manner by all tablet producers. It is open to conjecture
whether this 40 mg/kg dosing, which is a direct extrapola-
tion from adults, is appropriate for young children as
generally a nonlinear relationships exists. Validation of
this simple dosing regimen awaits the collection of future
pharmacokinetic and pharmacodynamic evidence which
may encourage the use of 60 mg/kg (see below) or even
higher levels, and further consideration in a revised drug
licensing schedule.Box 1. PZQ height pole: how low could you go?
In veterinary medicine, weighing facilities of large animals are
typically lacking yet many anthelminthics are administered upon
consideration of an animal’s body weight. Thus, other biometric
proxies of weight have been sought, height being the most
important, which is often, but not always, strongly correlated to
body weight. Hall et al. [61] first proposed the use of a height pole for
administration of PZQ in children, as later endorsed by the WHO [62].
In its first design, the lowest height division was at 110 cm denoting
1.5 tablets and upon early experiences in African primary schools
needed to be extended downwards to 94 cm offering a new height
range for administration of 1 tablet to children in reception class.
Further downward extension and biometric optimisation of this
height pole was needed for even smaller children. Using biometric
data from over 165 000 preschool-aged children (0–6 years of age,
60–110 cm in height) from 36 African countries, new tablet divisions
?
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Figure I. The current WHO height pole with a lower height threshold of 94 cm canno
extended dosing pole was needed for administration of PZQ for infants and preschoo
extended (right) height pole with new 0.75 (3/4) and 0.5 (½) tablet divisions. (b) Theore
60 cm thresholds with best targeted dose of 40 mg/kg denoted by a red arrow, with aSecond blocks off on PZQ treatment: taste and
formulation
Other concerns about administration of PZQ include the
difficulties of children swallowing the large, cumbersome
and bitter-tasting tablets, where risk of rejection and
possibilities of choking should be considered [6,24]. Tablets
can be easily crushed and mixed with honey or flavoured
juice to make them more palatable and easily swallowed
[26]. Of note is that the unusual flavour of PZQ (a racemate
of dextro- and laevo-isomers) is not always recognised by
younger children as it is in older counterparts or adults,
perhaps due to a maturing palate of the developing child or
inexperience of flavours. A liquid suspension of PZQ (Epi-
quantel1) is manufactured by EIPICO and licensed in
Egypt for school children. Epiquantel1 is frequently re-
ferred to as a syrup formulation, for its flavour is strongly
masked by aniseed. This in itself is not to the taste of all.were investigated to give dosing within the acceptable range of 30–
60 mg/kg. This newly optimised dose pole (Figure Ia) offers dosing
with a single 600 mg (height: 99–110 cm), 0.75 (3/4) (height: 83–99 cm),
and 0.5 (½) (height: 66–83 cm) tablet divisions, with over 95% of
children receiving an acceptable dose (Figure Ib). In addition, by
raising the single tablet threshold from 94 cm to 99 cm drug wastage
could be reduced, which at the NCP level may have considerable
drug savings [9,25,26]. These data also have bearings on the use of
other height poles for treatment of young children with drugs that
need consideration of body weight (e.g., antimalarials). Similarly, if
doses of PZQ at differing levels are needed, that is, at 60 mg/kg,
specific tailoring of an alternative height pole is possible. None-
theless, care is needed when such tools are rolled out into field
application to ensure that drug-specific height poles are not mixed
up between applications.
TRENDS in Parasitology 
Theorecal dosage given in mg/kg
36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100
Angola
Chad
Egypt
Liberia
Mozambique
Senegal
Togo
Zimbabwe
Burkina Faso
Congo (Brazaville)
Ghana
Malawi
Niger
Sao Tome e Principe
Uganda
Burundi
Cote d’Ivoire
Kenya
Mali
Nigeria
Swaziland
Zambia
Benin
Comoros
Ethiopia
Madagascar
Namibia
Sierra Leone
Tunisia
t be used for dosing children smaller than the one depicted and a downwardly
l-aged children without recourse to weighing scales. (a) Original WHO (left) and
tical cross-country validation of the extended height pole with 99 cm, 84 cm, and
cceptable dosing (30–60 mg/kg) indicated within the grey box.
199
Review Trends in Parasitology April 2013, Vol. 29, No. 4Contraindications include use in patients with ocular cys-
ticercosis or those with a general intolerance to PZQ and
breast-feeding mothers should suspend giving their breast
milk to children for 72 h after treatment [4].
The Epiquantel1 formulation comes in 15 ml dark glass
bottles with a concentration of 600 mg of PZQ per 5 ml of
fully mixed suspension. For dosing, each bottle also comes
with a small plastic measuring cup with a 5 ml division,
conveniently capping the sealed metal bottle top. As part
of the six-country WHO study, although there were some
positive considerations to its use, in terms of acceptability
and parasitological performance it was judged to be no
better than crushed or broken tablet alternatives [4].
Disadvantages included the large packing and storage
volume which was cumbersome in comparison with exist-
ing tablets. This caused significant problems in logistics
even in the small-scale study, predicting later problems in
large-scale supply chain management and distribution.
Perhaps more importantly, however, was the limited
availability of Epiquantel1, which is produced in an ad
hoc manner by EIPICO and is an expensive alternative
making it financially unattractive. In line with new WHO
general guidelines for paediatric medicines that promote
the use of water-dispersible tablets, it was concluded that
Epiquantel1 offered no significant improvement over
crushed or broken tablets and that the latter should be
continued to be used until an appropriate paediatric for-
mulation becomes available [4]. Another recommendation
was that PZQ could be delivered and administered to
afflicted communities on the back of the Expanded Pro-
gramme of Immunisation (EPI) campaigns which have
highly proven levels of outreach into sub-Saharan African
communities as supported by major international agen-
cies (e.g., UNICEF) [4].
Focus on Uganda: evidence from the SIMI cohort
November 2012 saw the end of a 4-year project funded by
the Wellcome Trust entitled Schistosomiasis in Mothers
and Infants (SIMI) [26]. The major aim of SIMI was to
conduct a novel longitudinal cohort study assessing the
need for and performance of crushed PZQ in terms of safety
and parasitological cure in six villages on the lakeshore of
Albert and Victoria. The strategy behind this study was toTable 1. Prevalence of intestinal schistosomiasis across the SIMI 
Environment Diagnostic Baseline %
(95% CI)
3-mont
(95% CI
Lake Alberta Kato–Katz 44.5%
(40.3–48.7)
ND 
(n = 572) Urine CCA 59.3%
(54.9–63.5)
52.1%
(47.4–56
SEA-ELISA 72.0%
(68.1–75.7)
ND 
Lake Victoriaa Kato–Katz 13.2%
(10.8–16.0)
ND 
(n = 639) Urine CCA 43.2%
(39.2–47.2)
39.7%
(35.4–44
SEA-ELISA 40.8%
(37.0–44.8)
ND 
aIn comparison to baseline, the average cohort recovery at each follow-up time point wa
with minimal subsequent drop-outs. During an 18-month study period, as estimated by
public health problem despite access to PZQ.
200emulate future PC within this setting but also to assess
how often young children should be retreated. It may be,
for example, that a single PZQ treatment might be suffi-
cient to stamp out their infections over a 2-year period.
Retreatment periods need to be set against actual levels of
reinfection which in turn need to be assessed with pres-
ently available diagnostics [16].
Over an 18-month period, the children (n = 1211) and
their mothers were followed at five time points. Key
results show that nearly half of the children aged 3 months
and above have active infections (Table 1) [16]. More
startling was that the levels of reinfection, especially on
the Lake Albert shoreline, were so substantial such that
even within a 6-month period following from two PZQ
administrations had little concrete impact in terms of
diminishing local prevalence. The situation in Lake Vic-
toria was more favourable, probably due to a slower gen-
eral transmission dynamic [16]. Assessing the risk of
infection and levels of reinfection in young children is
problematic owing to the distinctions between active
and passive water contact mechanisms [1]. A pilot study
in Lake Albert attempted to explain why transmission
seemed to be so high. Using a novel application of global
position system (GPS) data loggers (Box 2), young children
were shown to typically have up to 30 min of active daily
water contact in addition to more cryptic passive water
contact levels [27]. When taken together, however, this
revealed an astonishing amount of water contact risk and
pointed towards a stable but previously cryptic transmis-
sion group within the community.
In search of the best diagnostics, a combination ap-
proach was taken bringing to the field best available tools
[16,28–30]. For faecal examination, consecutive 2-day
stool specimens were collected and each examined by
duplicate Kato–Katz thick smears with microscopy. To
bolster this, urine circulating cathodic antigen (CCA) dip-
sticks were used together with analysis of sera from
clotted finger-prick blood using a commercially available
ELISA kit, detecting host IgM/G antibodies to schistosome
soluble egg antigen (SEA). Initial studies within a subset
of children, when additional faecal concentration exami-
nation techniques were applied, found that schistosome
antigens in urine, eggs in stool, and host antibodies to eggsyoung child cohort
h %
)
6-month %
(95% CI)
12-month %
(95% CI)
18-month %
(95% CI)
30.7%
(26.0–35.7)
37.6%
(32.6–42.7)
Cohort
closed
.7)
63.4%
(58.4–68.2)
51.0%
(45.9–56.2)
–
83.2%
(79.2–86.7)
87.2%
(83.5–90.4)
–
7.5%
(5.2–10.4)
14.5%
(11.3–18.3)
11.1%
(8.2–14.5)
.0)
40.2%
(35.7–44.8)
40.7%
(36.0–45.5)
34.2%
(29.7–39.0)
43.6%
(39.2–48.2)
26.4%
(22.3–30.8)
47.1%
(42.3–51.9)
s 70%, that is, an initial loss of approximately 30% at 6-month follow-up thereupon
 different diagnostic methods, intestinal schistosomiasis is shown to be a chronic
Box 2. Assessing risk of exposure in young children
For schistosome infection to take place requires the direct contact of
skin and schistosome cercariae, notwithstanding the oral route of
infection through the buccal mucosa. There has been a long history
of assessment of environmental risk of schistosomiasis which has
until recently relied upon observations of water contact as directly
observed by field staff with tally sheets or on recalled histories of
exposure upon interview questionnaire, both of which attempt to
estimate skin immersion times. Young children present unique
problems in being unable to answer questions and are generally less
ambulatory in water than their older counterparts. The latter may
have a subtle bearing on the efficacy of cercarial penetration as
younger children stay relatively static in water margins being largely
unable to swim and are simply content to dabble [1]. Estimating the
level of exposure risk is important as it is often a predictor of
reinfection and therefore the periodicity of retreatment with PZQ. By
taking advantage of cheap GPS data logging technology and
developing a custom-made Velcro arm strap (Figure Ia), Seto et al.
[27] attempted to measure the levels of direct water contact of young
children along the shoreline of Lake Albert, Uganda. Over a 3-day
study period, time spent at the immediate lakeshore was calculated
and found to be associated with egg-patent prevalence at baseline
and subsequent parasitological follow-up. Comparing the GPS data
logging patterns of mothers and children inferred that a social
network of interpersonal interactions existed positively associated
both with the number and duration of peer interaction, suggestive of
strong sociocultural factors associated with water contact behaviour
[63]. Although useful, this technology does have some limitations in
imprecision as shown by the two photographs (Figure Ib). Quantify-
ing the risk of exposure from directly drawn lake water in jerry cans is
problematic but immersion studies using laboratory bred mice
confirmed the occurrence of viable cercariae in the Lake Albert
setting [64].
(a) (b) Key water contact behavioursGPS data logging apparatus
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Figure I. At an early age, first water contact typically occurs by passive mechanisms (i.e., being bathed) before a later gradual transition towards active mechanisms as
the child is able to enter water alone. (a) The time, place, and duration of high-risk activities along the shoreline can be estimated by GPS data logging devices, which
may be worn on the upper arm or wrist by study participants thus enabling a digital track-log of putative active water contact on the water margins. (b) GPS data logging
approaches may, however, be confounded by specific behaviours, for example, (left) although the child may be in a high spatial risk zone, (s)he is not at immediate risk
due to being carried; however, being bathed with jerry can collected water is a high-risk activity (right), although it is difficult to define spatially within the lake shoreline
context.
Review Trends in Parasitology April 2013, Vol. 29, No. 4demonstrated a general prevalence of 47.5%, by a positive
criterion from at least one diagnostic method. Although
children as young as 6 months old could be found infected,
the average age of infected children was between 3.25 and
3.75 years, when diagnostic techniques all became broadly
congruent [31]. The prevalence of intestinal schistosomi-
asis across the five time points is shown in Table 1, which
despite treatment with PZQ shows little tangible signs of
abating and without treatment would have been more
alarming [16].
Another open question was selection of which diag-
nostic tool to choose to best track the reinfection dynam-
ics across these children [32]. This might also prove
useful for a future selective treatment rather than a
mass treatment approach. Diagnostic scores from a totalof 925 children across a 12-month period were available
for comparison. As a point-of-care diagnosis, the urine
CCA dipstick test achieved sensitivity and specificity
values ranging from 52.5–63.2% to 57.7–75.6%, respec-
tively, with faecal microscopy achieving very high spe-
cificities (>87%) but sensitivities as low as 16.7% upon
comparison to pooled diagnostic scores per child. The
urine CCA test was shown to be more effective than
faecal microscopy of a single stool sample and was not
significantly impacted by PZQ treatment history or coin-
fections with other intestinal helminths [32]. Although
its outlook in application is promising, it is yet to be
proven how the urine CCA test could be best used in
future mapping or selective treatment initiatives given a
general reluctance of many implementation agencies201
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they appear [20,33,34].
Consequences of early schistosomiasis: old markers of
morbidity
Faecal or urine egg counts have been the cornerstone of
measurements associated with morbidity in school chil-
dren for many years [33]. Whether they are entirely ap-
propriate in preschool children is open to conjecture.
More broadly, there is a limited repertoire of field-applica-
ble tests for direct assessment of morbidity [35] and
little application of these in the setting of young children
where infections are typically of ‘light intensity’ at least on
the basis of captured egg excretion using standard urine or
faecal sampling. Nonetheless, macrohaematuria, micro-
haematuria, and proteinuria (as assessed by reagent
strips), and other urine abnormalities, have been found
in young children in Schistosoma haematobium-endemic
communities [7,6,36–38]. Perhaps the most surprising was
the study by Sacko et al. who documented astonishing
levels of upper and lower urinary tract damage as seen
upon ultrasonography, some of which was still persistent
after PZQ treatment [4].
In Schistosoma mansoni-endemic areas, visible or
reported blood in stool (as described by the child’s mother)
has been documented [39,40]. Liver and spleen damage at
this early age is known by palpation of enlarged and
texture-hardened organs [41,42]. Liver fibrosis and peri-
portal thickening has been observed in infants and pre-
schoolers in S. mansoni-infected communities [41,43].
Although anaemia is often associated with schistosomia-
sis, assessing this in younger children is confounded by
coinfections, most notably malaria. Recent work in young
Ugandan children has found that anaemia is mostly at-
tributable to malaria rather than intestinal schistosomia-
sis [44]. By contrast, in West Africa, there was some
evidence of an association between anaemia and S. hae-
matobium infection in younger children [45].
Consequences of early schistosomiasis: new markers of
morbidity
In a novel attempt to identify markers of intestinal mor-
bidity in young children, Betson et al. field-tested faecal
calprotectin ELISAs and faecal occult blood (FOB) rapid
diagnostic tests (RDTs) concurrently with questionnaire-
based methods enquiring about a history of blood in stool,
diarrhoea, and abdominal pain (as reported by the child’s
mother). Although no association between egg-patent
schistosomiasis and faecal calprotectin was observed, a
strong positive association with FOB and symptoms
reported by mothers was detected [40]. The association
between S. mansoni infection and FOB (but not symptoms
reported by the mothers) was maintained after one or two
doses of PZQ over a 12-month study period [39]. This
suggested that the FOB RDT was a useful marker for
assessing intestinal morbidity in young children at the
community level and monitoring changes in morbidity
after mass PZQ treatment. Although the production and
availability of FOB RDTs is insecure, even within the UK,
they have again been used in Uganda during a PZQ efficacy
study where declines in FOB were observed 24 days after202treatment (A. Bustinduy et al., unpublished). The field
technology for detection of faecal calprotectin has also
changed with the availability of a commercially available
RDT and cassette reader which has overcome several
cumbersome aspects of ELISA. With some exceptions,
faecal calprotectin levels seem to increase 24 days after
PZQ treatment pointing towards rather complicated in-
flammation biology of the mucosal surface of the bowel (A.
Bustinduy et al., unpublished).
A novel field-applicable approach for assessing urinary
tract and bladder wall pathologies in S. haematobium-
endemic communities is to measure urine albumin levels
using an Albumin-HemoCue photometer [46]. Raised al-
buminuria was shown to be a promising marker of pathol-
ogy in school children and more recently albuminuria was
found to be associated with both egg-patent S. haemato-
bium infection and microhaematuria in young children in
Malawi (H. Poole, MSc thesis, Liverpool School of Tropical
Medicine, 2012). In this setting, albuminuria was also
strongly correlated with infected cases as identified by
serology, suggestive almost of equal diagnostic sensitivity
and specificity. This latter finding is particularly exciting
as the search for the most sensitive point-of-care test for
urogenital schistosomiasis continues, which will also prob-
ably have bearing on detection methods for female genital
schistosomiasis [47].
Early schistosomiasis: chronic infections and poor cure
rates
Evidence from the WHO six cross-country study showed
that cure rates with PZQ were satisfactory [4] but intes-
tinal schistosomiasis is a persistent and chronic infection
in young children in the lakeshore settings of Uganda
(Table 1) [16]. It is therefore perhaps ambitious to assume
that PZQ alone will be able to eliminate sufficiently all
infections in this setting without recourse to more aggres-
sive use of treatments and complimentary measures [48].
It is known, for example, that the present administration
and dosing at 40 mg/kg does not always effect a full
parasitological cure. This is often alongside coadminis-
tration of artemisinin-based combination therapy (ACT)
for management of concurrent malaria, where the arte-
mether component is thought to have some antischisto-
some activity on juvenile worms [49], but this appears
unfounded at the current antimalarial dosing in the SIMI
cohort [16].
From a total of 369 children found to be egg-patent for
intestinal schistosomiasis, 305 were followed up 3 to 4
weeks after PZQ treatment and infection status reassessed
using a variety of methods. Although the overall observed
parasitological cure was 56.4%, a significant difference was
found between a subset of children who had a history of
multiple PZQ treatments (between one and four adminis-
trations over an 18-month period), where cure rate was
41.7%, and those who had never received treatment (cure
rate was 77.6%) [10]. The cure rate was clearly lower in
younger children (<3 years of age) and in those with a
history of previous treatment. Cure rate, but not egg
reduction rate, was also lower in children with heavier
preintervention infection intensity. Recent work in Ugan-
dan children suggests that higher than recommended
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The difference in egg-clearance cure rate 4 weeks after
treatment was 82% compared with 68% for different dosing
strategies (60 mg/kg vs 40 mg/kg). Egg reduction rates
ranged from 91% to 82% in the 60 mg/kg and 40 mg/kg
arms, respectively. Further pharmacokinetic data are soon
to follow and may well challenge the current treatment
recommendations for S. mansoni in children of all ages (A.
Bustinduy et al., unpublished).
Rather unsatisfactory cure rates in young children have
now been reported in Niger. Using Epiquantel1, moderate
to high levels of efficacy against S. haematobium were
found with cure rates of 85.7%. This contrasted sharply,
however, with that for S. mansoni which was 50.6%
against clearance [7]. The marked differences in species-
specific drug performance call for further research into
optimising treatment for each schistosome species whilst
remaining mindful of any revised drug licensing [7,10].
There is also an ongoing debate concerning the suitability
of using parasitological cure in terms of treatment cam-
paigns, owing to a variety of issues best described in papers
by Montresor et al. [11,50].
Towards better access and formulations of PZQ
Before the reductions in price of PZQ there was actually a
slow uptake of this drug as treatment of choice, the reasons
for which were analysed by Reich and Govindaraj [51],
when PZQ first entered the market, aspects related to its
access and pricing had not been sufficiently addressed
creating a lasting detrimental legacy. Other factors also
played contributory roles: the reluctance of donor agencies
in engaging early on in purchasing initiatives, failure of
non-governmental organisation (NGO)-based implementa-
tion agencies to sustain control activities in the long term
or expand to the national level, the lack of decision-making
autonomy of low-income countries to leverage or synergise
with donor agencies and rather simply put, many endemic
countries lacked the infrastructure to participate appro-
priately in international tendering [51].
With the advent of the Schistosomiasis Control Initia-
tive [52] some of these issues were resolved [53]. Until very
recently, the global supply chain of PZQ was restricted [54],
largely due to the available commercial producers being
reluctant to engage in scaling-up of production until better
estimates of global drug consumption/needs were in place
to create a sustainable ‘market’ [17]. With the London
Declaration on Neglected Tropical Diseases (LDNTDs) this
picture has changed dramatically. A cardinal step was
taken by the WHO in setting out a clear strategy of the
scale-up of PC and assistance to countries to assess their
future PZQ needs until 2020 and beyond, but these esti-
mates do not factor in the treatment needs of infants and
preschool children in their calculations [33].
Responding to these fundamental changes before the
LDNTDs, in 2007 Merck (Germany) started its PZQ dona-
tion programme to the WHO, committing to donate 200
million tablets of PZQ over the next 10 years with the
company increasing its donation, as spurred on by the
LDNTDs meeting, to delivering 250 million tablets per
year in the medium term. This would correspond to a
treatment of approximately 100 million school childreneach year. Moreover, realising that this formulation was
not particularly paediatric friendly, because off-label use
(use beyond the terms of the license) outside of the dona-
tion programme implied that its performance in terms of
efficacy and safety had not been sufficiently studied to
ensure that the current formulation of PZQ product is
delivering its full therapeutic potential. Merck has com-
mitted therefore to addressing the treatment needs of
infants and preschool children by developing an appropri-
ate paediatric formulation.
From a pharmaceutical perspective, this is a significant
task and to close this PZQ treatment gap, Merck started a
public–private partnership (PPP) together with Astellas
Pharma, the Swiss Tropical and Public Health Institute,
and TI Pharma, a non-profit organisation. The overall
objective of this partnership is to develop a PZQ formula-
tion that is appropriate for the treatment of children
covering the age range of 3 months to up to 6 years with
formal product licensing after full development [47].
The project is currently in the preclinical phase for
development of the appropriate formulation and will enter
clinical development by 2014. Future research necessary to
complete its registration is to investigate the optimum PZQ
dosage to ensure an effective worm kill, concurrently with
improvements in its ease of administration, for example,
by community drug distributors. However, the success of
such initiatives will depend not only on the commitment of
the partners but also on the creation and implementation
of a favourable ground for dialogue and interaction be-
tween afflicted populations, researchers, and clinicians as
well as the public sector (e.g., health systems, control
programmes, drug regulators, etc.). In the longer term,
financial incentives and mechanisms need to be put in
place within the pharmaceutical sector to ensure that
access to the new formulation is sustainable after comple-
tion of the PPP. Some of these future issues in this paedi-
atric setting will parallel the previous problems in general
access to PZQ as discussed comprehensively by Reich [55].
Schistosomiasis alongside other paediatric infections
In Africa, polyparasitism is perhaps the norm rather than
the exception [56]. This milieu of parasites, other infectious
diseases, as well as underlying nutrition states frankly
questions the fundamental raison d’eˆtre of monospecific
interventions, especially when rolled out into a disease-
endemic community. Of the long list of infections, two
perhaps rank higher than most – HIV and malaria – each
being well known in the context of mortality and morbidity
of young children. Children born to HIV-infected mothers
are at risk of acquiring the disease and once infected have a
poor clinical outcome if infections are left unchecked.
Infants are particularly prone to malaria due to a naı¨ve
immune system unable to deal with invading parasites
that can quickly wreak havoc. Nonetheless, both diseases
are amenable to chemotherapy, HIV with highly active
antiretroviral therapy (HAART) and malaria with ACT,
which has become the front-line treatment for home-based
management of malaria.
Should use of PZQ be considered more holistically
within a disease-endemic community when other inter-
vention schemes are ongoing? All should agree that203
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matter where their illnesses come from; however, ambi-
tion and reality sometimes become confused when put
into practice on the ground. Pairing certain treatment
combinations might lead to overburdening fragile health
systems when distributors of medications are stretched in
time and resources [57]. From a biological perspective,
there may be unforeseen drug–drug interactions which
alter their pharmacokinetic or pharmacodynamic profiles
leading to diminished performance [20,58,59]. Evidence-
based medicine in this setting is particularly weak as
there are few clinical trials conducted in healthy adult
volunteers in endemic disease settings and even fewer so
in the paediatric setting. Children should be the priority
target, as a historically vulnerable population frequently
neglected behind their adult counterparts, for longitudi-
nal cohort studies and closely monitored field–epidemio-
logical studies to ensure treatments are rolled out as
safely as possible.
Towards young children free from schistosomiasis
What steps are now needed to be taken to resolve this ‘PZQ
treatment gap’? With the changing WHO guidelines and
future availability of a paediatric-friendly formulation
from PPP, there is much optimism for African children
to have better access to medication. To scale-up, PZQ
delivery systems need to be securely embedded within a
strong public health platform such as EPI. To achieve this,
there needs to be strong communication between interna-
tional donors for provision of funds and synergism with
effective governments with clear political will and commit-
ment to maintain a robust delivery of medicines. Although
there are concerns that PZQ might not be fully effective in
the treatment of schistosomiasis, this should not be a block
to roll out of treatment in younger children but more of an
indictment to maintain a closer monitoring and surveil-
lance system to achieve healthier children. So to close as
succinctly as possible, let them now be treated!
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